pravastatin
AssetAlso PRAVASTATIN SODIUM
Inhibits HMG-CoA reductase to reduce endogenous cholesterol synthesis.
- Stage
- Approved
- Modality
- Small molecule
- Target
- Lipid and ceramide metabolism
- 3
- Indications
- 100
- Trials
- 3
- Developers
Indications
4No named disease
Approved, accessdata.fda.gov, 7 Oct 2026
Actue coronary syndrome
Phase 3, Completed, NCT00382460, clinicaltrials.gov, 7 Oct 2026
Hypercholesterolemia
Phase 3, Completed, NCT00529178, clinicaltrials.gov, 7 Oct 2026
1 more
In the full profile
- Targets and what it contains2
- Owner and partners3
- Trials100
- Evidence for its targets3
- Competitors12
- Aging relevance1
Every asset’s record: target, stage, trials and the evidence behind it.
Updated 8 Oct 2026, 11 sources